Tag #Astrazeneca

Showing 1 to 12 of 20 results

bbc.com

🌐 85% Global Worthiness

Sep 25, 04:17

UK Medicine Prices Must Rise to Attract Pharmaceutical Investment, Says Science Minister

Science minister Patrick Vallance says the UK must raise NHS medicine prices to prevent pharmaceutical companies from pulling investment from the country, following recent project cancellations by major drugmakers.

UK Medicine Prices Must Rise to Attract Pharmaceutical Investment, Says Science Minister

Science minister Patrick Vallance says the UK must raise NHS medicine prices to prevent pharmaceutical companies from pulling investment from the country, following recent project cancellations by major drugmakers.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary reason for the proposed increase in NHS medicine prices?

To attract and retain pharmaceutical investment in the UK. Several major drug companies have recently cancelled or paused UK projects due to low drug prices, lack of government investment, and international price pressures. Price increases are deemed necessary to reverse this trend.

mk.ru

🌐 90% Global Worthiness

Aug 31, 13:16

New Drug Baxdrostat Shows Significant Blood Pressure Reduction in Resistant Hypertension

A new drug, baxdrostat, has demonstrated significant blood pressure reduction in a global trial involving 796 patients with resistant hypertension, lowering systolic blood pressure by approximately 9-10 mmHg and achieving normal blood pressure in roughly 40% of patients.

New Drug Baxdrostat Shows Significant Blood Pressure Reduction in Resistant Hypertension

A new drug, baxdrostat, has demonstrated significant blood pressure reduction in a global trial involving 796 patients with resistant hypertension, lowering systolic blood pressure by approximately 9-10 mmHg and achieving normal blood pressure in roughly 40% of patients.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the key finding of the BaxHTN trial regarding baxdrostat's efficacy in treating resistant hypertension?

The BaxHTN trial, involving 796 patients across 214 clinics globally, showed that baxdrostat significantly reduced blood pressure in patients with resistant hypertension. Systolic blood pressure decreased by approximately 9-10 mmHg more than in the placebo group, a reduction linked to significantly lower cardiovascular risk. Around 40% of patients taking baxdrostat achieved normal blood pressure versus 18.7% on placebo.

theguardian.com

🌐 85% Global Worthiness

Jul 29, 22:16

AstraZeneca's US Focus Raises Concerns About UK Commitment

AstraZeneca CEO Pascal Soriot's recent comments praising the US pharmaceutical market and his silence on a potential US stock market listing raise concerns about the company's commitment to the UK, highlighting funding disparities and potential relocation costs.

AstraZeneca's US Focus Raises Concerns About UK Commitment

AstraZeneca CEO Pascal Soriot's recent comments praising the US pharmaceutical market and his silence on a potential US stock market listing raise concerns about the company's commitment to the UK, highlighting funding disparities and potential relocation costs.

Progress

52% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

How do the UK's funding policies for pharmaceutical innovation and NHS drug pricing contribute to AstraZeneca's apparent shift in focus towards the US?

Soriot's focus on the US contrasts with his vague assurances regarding the UK, especially concerning the stock market listing. This silence, combined with criticism of the UK's pharmaceutical funding model (0.3% GDP investment vs. 0.8% in the US), suggests a potential shift of AstraZeneca's primary focus. The lack of a clear commitment to the UK listing is especially concerning given the government's initiatives to revitalize the London stock market and establish the UK as a life sciences leader.

dailymail.co.uk

🌐 85% Global Worthiness

Jul 3, 01:13

AstraZeneca's Potential US Relocation Could Cost UK £1 Billion Annually

AstraZeneca, a £161 billion pharmaceutical company, is considering moving its stock market listing from London to Wall Street due to concerns over UK drug pricing and regulatory issues, potentially costing the UK Treasury £1 billion annually in taxes and impacting the UK's economic growth.

AstraZeneca's Potential US Relocation Could Cost UK £1 Billion Annually

AstraZeneca, a £161 billion pharmaceutical company, is considering moving its stock market listing from London to Wall Street due to concerns over UK drug pricing and regulatory issues, potentially costing the UK Treasury £1 billion annually in taxes and impacting the UK's economic growth.

Progress

68% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

How does AstraZeneca's potential departure reflect broader trends in UK business and the government's economic strategy?

The potential departure of AstraZeneca reflects broader concerns about the UK's business environment. The company's estimated £300 million annual stamp duty contribution and hundreds of millions more in tax from dividends highlight the significant financial implications. This, coupled with the loss of payroll and corporation taxes, underscores the systemic risk of companies leaving due to perceived regulatory hurdles and unfavorable policies.

dailymail.co.uk

🌐 85% Global Worthiness

Jul 2, 10:12

AstraZeneca Weighs US Stock Market Listing, Threatening London's Status

AstraZeneca, the UK's largest listed firm, is considering moving its stock market listing to the US due to frustrations with UK regulations and pricing disputes, potentially causing significant damage to the London Stock Exchange.

AstraZeneca Weighs US Stock Market Listing, Threatening London's Status

AstraZeneca, the UK's largest listed firm, is considering moving its stock market listing to the US due to frustrations with UK regulations and pricing disputes, potentially causing significant damage to the London Stock Exchange.

Progress

56% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

How do UK regulations on medicine approvals and pricing disputes with the NHS contribute to AstraZeneca's consideration of a US listing?

AstraZeneca's potential relocation reflects broader concerns about the UK's business environment. The company's frustration with UK regulations, coupled with its strong US and Chinese market presence, make a US listing appealing. This decision, if implemented, could trigger a domino effect, prompting other large British firms to consider similar moves.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 10, 01:18

Trump's Tariff Threat Wipes £14 Billion Off UK Drugmakers

President Trump's threat of US tariffs on pharmaceutical imports caused a £14 billion loss in market value for AstraZeneca and GSK, highlighting the reliance of British drugmakers on US sales and sparking concerns about global supply chain disruptions and potential public health risks due to planned...

Trump's Tariff Threat Wipes £14 Billion Off UK Drugmakers

President Trump's threat of US tariffs on pharmaceutical imports caused a £14 billion loss in market value for AstraZeneca and GSK, highlighting the reliance of British drugmakers on US sales and sparking concerns about global supply chain disruptions and potential public health risks due to planned...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of President Trump's tariff threat on major UK pharmaceutical companies' market capitalization?

Following President Trump's announcement of potential tariffs on pharmaceutical imports, shares in AstraZeneca and GSK plummeted, resulting in a combined £14 billion loss in market value. AstraZeneca experienced a 6.8% drop, while GSK fell by 5.7%. This reflects the significant reliance of these companies on US sales.

theguardian.com

🌐 85% Global Worthiness

Sep 12, 22:19

AstraZeneca Halts UK Investment, Exacerbating Life Sciences Crisis

AstraZeneca paused a planned £200 million Cambridge expansion and scrapped a £450 million vaccine facility investment, mirroring similar decisions by Merck and Sanofi, raising concerns about the UK's competitiveness in the life sciences sector.

AstraZeneca Halts UK Investment, Exacerbating Life Sciences Crisis

AstraZeneca paused a planned £200 million Cambridge expansion and scrapped a £450 million vaccine facility investment, mirroring similar decisions by Merck and Sanofi, raising concerns about the UK's competitiveness in the life sciences sector.

Progress

56% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What is the immediate impact of AstraZeneca's decision to pause its UK investment?

AstraZeneca's decision halts a £200 million Cambridge expansion, eliminating 1000 expected jobs and completely stopping its previously announced £650 million UK investment package. This adds to the growing crisis in the UK life sciences sector.

us.cnn.com

🌐 85% Global Worthiness

Aug 30, 22:18

New Drug Shows Promise in Treating Resistant High Blood Pressure

An experimental drug, baxdrostat, effectively lowered blood pressure in a clinical trial involving 800 adults with resistant hypertension, offering a potential new treatment option.

New Drug Shows Promise in Treating Resistant High Blood Pressure

An experimental drug, baxdrostat, effectively lowered blood pressure in a clinical trial involving 800 adults with resistant hypertension, offering a potential new treatment option.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of the baxdrostat trial for resistant hypertension?

The trial, involving 800 adults with resistant hypertension, showed that 40% of patients taking baxdrostat reached healthy blood pressure levels at 12 weeks, compared to less than 20% on a placebo. Systolic blood pressure decreased by approximately 9-10 mm Hg more in the baxdrostat groups than in the placebo group, a reduction significant enough to lower cardiovascular risk.

dailymail.co.uk

🌐 85% Global Worthiness

Jul 23, 04:12

AstraZeneca's \$37 Billion US Investment Amid Tariff Fears

AstraZeneca plans to invest \$37 billion in the US, creating tens of thousands of jobs, amid President Trump's threatened pharmaceutical tariffs, raising concerns about the company potentially moving its primary stock market listing from London to New York.

AstraZeneca's \$37 Billion US Investment Amid Tariff Fears

AstraZeneca plans to invest \$37 billion in the US, creating tens of thousands of jobs, amid President Trump's threatened pharmaceutical tariffs, raising concerns about the company potentially moving its primary stock market listing from London to New York.

Progress

60% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What is the immediate economic impact of AstraZeneca's \$37 billion US investment on the UK?

AstraZeneca, a FTSE 100 drug maker, announced a \$37 billion investment in the US, creating tens of thousands of jobs. This follows threats of pharmaceutical tariffs from the US government and fuels concerns the company may move its primary stock market listing from London to New York.

theguardian.com

🌐 85% Global Worthiness

Jul 2, 22:13

AstraZeneca Weighs US Relocation Amid UK Disputes

AstraZeneca, facing disagreements with UK authorities over drug pricing and support, is considering moving its stock market listing and potentially its headquarters to the US, jeopardizing Britain's industrial strategy and London's financial standing.

AstraZeneca Weighs US Relocation Amid UK Disputes

AstraZeneca, facing disagreements with UK authorities over drug pricing and support, is considering moving its stock market listing and potentially its headquarters to the US, jeopardizing Britain's industrial strategy and London's financial standing.

Progress

56% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What specific factors within the UK's regulatory and commercial environment have driven AstraZeneca's consideration of moving to the US?

The potential relocation reflects AstraZeneca's frustration with the UK's regulatory and commercial environment for pharmaceuticals. Lower healthcare spending on new medicines in the UK compared to other countries, coupled with longer clinical trial times, contributes to this decision. This also highlights broader concerns among pharmaceutical companies about the European regulatory landscape.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 30, 04:15

AstraZeneca Shifts Production to US Amidst Europe's Lagging Pharmaceutical Investment

AstraZeneca CEO Pascal Soriot announced a shift of manufacturing to the US due to potential tariffs, highlighting Europe's lagging pharmaceutical investment and emphasizing the US's dominant role in funding pharmaceutical innovation; the company reported a 10% revenue increase for Q1 2025, with onco...

AstraZeneca Shifts Production to US Amidst Europe's Lagging Pharmaceutical Investment

AstraZeneca CEO Pascal Soriot announced a shift of manufacturing to the US due to potential tariffs, highlighting Europe's lagging pharmaceutical investment and emphasizing the US's dominant role in funding pharmaceutical innovation; the company reported a 10% revenue increase for Q1 2025, with onco...

Progress

48% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

How might the planned US tariffs on pharmaceutical imports affect the global pharmaceutical landscape, and what are the potential consequences for both US and European companies?

Pascal Soriot, AstraZeneca's CEO, warned Europe is falling behind in pharmaceutical investment compared to the US. He highlighted that the US's significant investment incentivizes companies to move jobs and research there. AstraZeneca's shift in manufacturing to the US demonstrates the impact of this imbalance, prompting calls for increased European investment to maintain competitiveness.

spanish.china.org.cn

🌐 85% Global Worthiness

Mar 26, 13:14

AstraZeneca Invests $2.5 Billion in China R&D Center

AstraZeneca is investing $2.5 billion in a new research and development center in Beijing, its sixth globally, to leverage China's growing pharmaceutical innovation and establish a key hub for global drug development, reflecting China's rising role in the industry and resulting in collaborations wit...

AstraZeneca Invests $2.5 Billion in China R&D Center

AstraZeneca is investing $2.5 billion in a new research and development center in Beijing, its sixth globally, to leverage China's growing pharmaceutical innovation and establish a key hub for global drug development, reflecting China's rising role in the industry and resulting in collaborations wit...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of AstraZeneca's $2.5 billion investment in a new R&D center in Beijing?

AstraZeneca, a multinational pharmaceutical company, is significantly increasing its investment in research and development (R&D) in China, aiming to leverage the country's growing innovation capacity. This $2.5 billion investment will establish a sixth global R&D center in Beijing, focusing on initial research and clinical development, and includes collaborations with local partners.

Showing 1 to 12 of 20 results